Sunpeaks Ventures Achieves Huge Rebound (SNPK)

Sunpeaks Ventures (OTC: SNPK) successfully continued its rebound today, rallying 43.2% on a second consecutive day to a share price of $0.063. Volume of the stock spiked to a total of 3.95 million shares, bypassing its average of 2.23 million. Sunpeaks Ventures’ huge rebound today may be giving investors a promising outlook for the stock’s performance next week.

Despite its recent rebound, shares of Sunpeaks Ventures have a total loss of 85.4% year-to-date. The stock had been steadily rallying since New Year’s Day until the peak price of $2.23 on April 17, 2012, when the share price of Sunpeaks Ventures started falling significantly.

Sunpeaks Ventures has been promoted by a huge number of newsletters. Global Marketing Media expects to be compensated $100,000 for a two-day marketing and promotional effort on Sunpeaks by Flip Ventures. There are 932 results found on stockpromoters.com regarding the stock promotion of Sunpeaks Ventures. The number may indicate duplicate entries. According to @pennystock24, Penny Stock Wizards promoted Sunpeaks Ventures today.

Sunpeaks Ventures hasn’t issued a press release for almost two months, despite some Edgar filings. Here are some headlines for the company from early May that are worth looking at:

  • May 8, 2012: Sunpeaks Ventures and its wholly owned subsidiary Healthcare Distribution Specialists, announced that Sunpeaks has entered into a marketing and sponsorship agreement with a Division I-A college sports program.
  • May 3, 2012: Sunpeaks Ventures and its wholly owned subsidiary Healthcare Distribution Specialists, announce that HDS has entered into an advertising agreement with Pulse Advertising for the marketing of Clotamin through a campaign of recorded radio commercials and premium online advertising.
  • May 1, 2012: Sunpeaks Ventures filed a Complaint in the Circuit Court for Montgomery County, Maryland against Deal Flow Media, Thomas Siudak, Red Carpet Books, and Bill Martlink alleging that they engaged in a systematic series of false, defamatory, and malicious statements as part of a larger conspiracy in an attempt to cause harm to the company.

Sunpeaks Ventures and its wholly owned subsidiary Healthcare Distribution Specialists, is a nationally focused, value-added distributor of specialty drugs and over-the-counter branded multivitamins to the healthcare provider market.

HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.

Published by Fiona Gibson

Fiona is a finance graduate and an expert in analyzing market trends.